SCHEMBL16789933

SCHEMBL16789933

CCOC(=O)[C@H]1CCN(C(=O)OC(C)(C)C)C[C@@H]1N1CCCC(I)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ EPHX1 P07099 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ GPR119 Q8TDV5 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16786560 0.87 MAPT (0.41) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL30471621 0.84 HPGD (0.39) ALDH1A1HPGDKDM4EGLARECQL
SCHEMBL16765208 0.84 HPGD (0.39) ALDH1A1HPGDKDM4EGLARECQL
SCHEMBL16765207 0.84 HPGD (0.39) ALDH1A1HPGDKDM4EGLARECQL
SCHEMBL30242034 0.84 MAPT (0.43) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL9962424 0.84 MAPT (0.43) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL18790622 0.80 MAPT (0.40) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL22240440 0.80 MAPT (0.37) ALDH1A1HPGDKDM4EGLARECQL
SCHEMBL23297080 0.78 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EGLARECQL
SCHEMBL23297076 0.78 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EGLARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174511-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. (US) 2023-06-08 — — US disclosed
US-11174243-B2 Succinate forms and compositions of Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2021-11-16 — — US disclosed
US-20210032218-A1 SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2021-02-04 — — US disclosed
US-20210017155-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2021-01-21 — — US disclosed
EP-3753934-A1 PYRIMIDINYL DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS Biogen MA Inc. (US) 2020-12-23 — — EP disclosed
EP-3385263-B1 PYRIMIDINYL TYROSINE KINASE INHIBITORS BIOGEN MA INC (US) 2020-07-22 — — EP disclosed
US-10618887-B2 Pyrimidinyl tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-04-14 — — US disclosed
US-20190047986-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2019-02-14 — — US disclosed
EP-2858499-B1 PYRIMIDINYL TYROSINE KINASE INHIBITORS BIOGEN MA INC (US) 2018-05-16 — — EP disclosed
US-9944622-B2 Pyrimidinyl tyrosine kinase inhibitors BIOGEN MA INC. (US) 2018-04-17 — — US disclosed
WO-2018017153-A1 SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. (US) 2018-01-25 — — WO disclosed
US-20160304494-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-10-20 — — US disclosed
US-9394277-B2 Pyrimidinyl tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-07-19 — — US disclosed
US-20150158843-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2015-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017155-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 ALDH1A1 3713/4885HPGD 3714/4885KDM4E 1291/4885
US-11174243-B2 Succinate forms and compositions of Bruton's tyrosine kinase inhibitors ABL1, SRC, BTK ALDH1A1 3327/4885HPGD 1531/4885KDM4E 1005/4885
US-20210032218-A1 SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS ABL1, SRC, BTK ALDH1A1 3327/4885HPGD 1531/4885KDM4E 1005/4885
US-20230174511-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 ALDH1A1 3781/4885HPGD 3961/4885KDM4E 1148/4885
US-20150158843-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 ALDH1A1 3713/4885HPGD 3714/4885KDM4E 1291/4885
US-20190047986-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 ALDH1A1 3713/4885HPGD 3714/4885KDM4E 1291/4885
US-20160304494-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 ALDH1A1 3713/4885HPGD 3714/4885KDM4E 1291/4885
US-10618887-B2 Pyrimidinyl tyrosine kinase inhibitors ABL1, BTK, ABL2 ALDH1A1 3713/4885HPGD 3714/4885KDM4E 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback